Drug Price Regulation in India: Balancing Pharmaceutical Innovation with the Right to Affordable Healthcare

Introduction: Healthcare Affordability as a Governance Challenge

Affordable medicines are essential to the effective realisation of the right to life under Article 21 of the Constitution. However, high medicine prices, substantial trade margins and uneven access to affordable alternatives can increase outofpocket expenditure (OOPE), pushing vulnerable households into financial distress.

India’s drugpricing framework, centred on the Drugs (Prices Control) Order (DPCO), 2013, and the National Pharmaceutical Pricing Authority (NPPA), must balance patient affordability, fair competition, medicine availability and incentives for pharmaceutical innovation.

Understanding India''s Drug Pricing Framework

• Essential Commodities Act, 1955: Section 3 empowers the Central Government to regulate essential commodities, including drugs, through appropriate control orders.
• DPCO, 2013: Provides the framework for fixing and regulating prices of specified medicines.
• National Pharmaceutical Pricing Authority (NPPA): Administers price controls, monitors compliance and takes action against overcharging.
• National List of Essential Medicines (NLEM): Identifies medicines considered essential for healthcare priorities and informs the scheduled drug price control framework.
• Scheduled formulations: Medicines included in the relevant schedule of the DPCO are subject to NPPA ceiling prices. Under the marketbased method, the ceiling price is generally based on the simple average price to retailer of qualifying brands with at least 1% market share by moving annual turnover, with a retailer margin incorporated as prescribed.
• Non scheduled formulations: Manufacturers generally have greater freedom to set launch prices, but increases in the maximum retail price are restricted to 10% during any 12month period under the DPCO framework.

Economic Dimension

• High trade margins: Large differences between procurement prices and MRPs can increase patients’ medicine expenditure.
• Market based pricing limitations: Where existing prices are already high, averaging market prices may produce ceiling prices that remain unaffordable.
• Industry incentives: Pharmaceutical firms require reasonable returns to support research, development, quality assurance and supply chain investment.
• Policy challenge: Price controls must prevent excessive pricing without creating shortages or discouraging the supply of essential medicines.

Social Justice and Public Health

• Catastrophic expenditure: Expensive cancer treatment, critical care medicines and long term therapies can impose severe financial burdens on households.
• Unequal access: Low income patients may delay treatment, discontinue medication or depend on cheaper but less accessible alternatives.
• Generic medicines: Quality assured generics can improve affordability, provided patients and healthcare professionals have confidence in their quality and therapeutic equivalence.
• Health equity: Access to essential medicines should not depend solely on a patient''s ability to pay.

Governance and Regulatory Dimension

• Coverage gaps: Price regulation applies differently to scheduled and non scheduled medicines, leaving scope for high launch prices in the latter category.
• Trade margin opacity: Limited transparency across manufacturers, distributors, hospitals and pharmacies can make it difficult to identify excessive margins.
• Hospital pharmacy practices: Patients admitted for treatment may have limited practical choice over where they obtain prescribed medicines.
• Enforcement challenges: Effective monitoring requires reliable transaction data, transparent pricing and timely action against violations.

Constitutional and Legal Dimension

• Article 21: The Supreme Court has interpreted the right to life to include important dimensions of health and human dignity. Affordable access to essential treatment is therefore a significant publicpolicy concern.
• Directive Principles: Article 47 directs the State to improve public health and nutrition.
• State responsibility: Regulation should protect patients from unreasonable barriers to essential treatment while ensuring the continued availability of medicines.
• Legal balance: Affordability objectives must operate through clear statutory powers, proportionate measures and transparent regulatory procedures.

Federal and Institutional Dimension

• Union level regulation: Drug price controls are primarily administered through the central regulatory framework.
• State level implementation: State drug controllers play important roles in drug quality enforcement and related regulatory functions.
• Institutional coordination: The Health Ministry, Department of Pharmaceuticals, NPPA and state authorities need coordinated data and enforcement mechanisms.
• Public healthcare: Strengthening government hospitals and affordable medicine outlets can reduce dependence on high priced private retail channels.

Pharmaceutical Innovation and Industrial Competitiveness

• Research and development: Excessively rigid pricing rules may affect incentives for developing innovative therapies, particularly where research costs and risks are high.
• Domestic manufacturing: Predictable regulation can support investment in APIs, formulations and quality assured generic production.
• Availability concerns: Poorly designed price controls can potentially affect the supply of low volume or costly medicines.
• Balanced regulation: Different approaches may be required for essential generics, patented medicines, orphan drugs and lifesaving therapies.

Structural Gaps in Drug Price Regulation

Way Forward: Towards Patient Centric Drug Pricing

• Expand targeted price regulation: Assess the need for additional controls on selected high cost, lifesaving non scheduled medicines using evidence on affordability, competition and availability.
• Rationalise trade margins: Examine margins across the supply chain and introduce proportionate, transparent controls where excessive margins are established.
• Strengthen generic prescribing: Promote prescribing by generic name in accordance with applicable professional regulations, alongside safeguards for quality, bioequivalence and patient safety.
• Improve price transparency: Make reliable information on ceiling prices, MRPs and lowercost equivalent medicines easily accessible.
• Strengthen hospital accountability: Ensure transparent medicine billing and meaningful patient choice wherever clinically and operationally feasible.
• Expand affordable medicine access: Strengthen Pradhan Mantri Bhartiya Janaushadhi Kendras and procurement systems for essential medicines.